Targeted therapy for canine osteoarthritis

The extraordinary value of veterinary dermatology specialists to general practitioners with Julia Miller

Light-based therapy for postoperative wound healing and more

Animal toxicity treatment with Erik Zager

Now Viewing

Targeted therapy for canine osteoarthritis

A new standard of care for the treatment of chemotherapy-induced diarrhea in dogs

How Dr Sue Ettinger treated chemotherapy-induced diarrhea in this intrapelvic sarcoma patient

The power of noninvasive shock wave therapy for pain management and rehabilitation

Endocrinology, thyroid, and breakthroughs in testing

Topical therapy: a critical piece of the dermatology puzzle

Breaking down the Nextmune line of topical dermatologic products

The next generation of allergy testing and immunotherapy

Creating inclusive spaces for the LGBTQ+ community in vet med

AI brings the reference lab into the clinic

How to inspire the next generation of veterinarians

Why shadowing makes all the difference for nurturing a career in vet med

The future of data-driven veterinary care

How digital cytology is bridging the gap for quality control and efficiency

Tackling canine separation anxiety with Dr Christopher Pachel

See the Calmer Canine separation anxiety treatment system in action

No-touch vitals monitoring for stress-free post-op recovery

The multimodal approach to the itchy pet: treating from a "whole-animal" perspective

Examining antimicrobial stewardship in veterinary dermatology

This content sponsored by Synovetin OA

This segment of dvm360® Live!™ features a clinical discussion with board-certified veterinary rehabilitation specialist Matt Brunke, DVM, DACVSMR, CCRP, CVPP, CVA. Brunke shares the concept of targeted therapy for treatment of canine osteoarthritis, which focuses on targeting the specific joint, rather than using systemic drugs.

Below is a partial transcript. See the video below for more:

Matt Brunke, DVM, DACVSMR, CCRP, CVPP, CVA: Targeted therapy, especially for [osetoarthritis]...because if you only have one arthritic joint, why are we giving systemic meds? While [they are] safe and efficacious, there's a chance that they could have issues. And if your only issue is in 1 elbow, then why not approach that 1 elbow, right?

Because arthritis is an inflammatory disease. It's a puffy joint; it's sore. I will always tell owners that it's, you know, it's like a rusted out hinge like a door. It doesn't bend as well, so it's going to impact their ability to move and stand and do all these things. And that's an uncomfortable thing, right? That stretch of that joint makes the nerve endings hurt [and] makes the inflammatory cascade keep happening. So, if that's the only problem, why are we trying to challenge it from a systemic approach? So, that's where targeted therapy came in.